SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 17, 2026

ZVRA

ZEVRA THERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonimmediate Processed2mo ago
Insider cluster: 2 insiders, $613K total
Actionable Insight • Neutral

Monitor for any pending earnings or catalyst events (e.g., FDA update, trial data) that could motivate the larger sale by the legal officer. Absent such context, this is routine insider diversification with no actionable signal. Wait for a cluster involving C-suite open-market purchases to consider a bullish read.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
ZVRA ▲ +1.99% at T+20d
NEUTRAL call +1.99% · α vs SPY +3.73% · entry $11.57 → $11.80
Next anchor: T+60d in 14d
Latest observation: T+47 -11.39% FF3 residual α
Entry = T+0 close
Aug 17, 2026
via day close
T+1d
+4.84%
call +4.84% · α +4.63%
$12.13
settled 2mo ago
T+5d
+4.06%
call +4.06% · α +4.26%
$12.04
settled 2mo ago
T+20d
+1.99%
call +1.99% · α +3.73%
$11.80
settled 6w ago
T+60d
Pending
in 14d

Price Chart

Loading chart...

Executive Summary

Two ZVRA insiders—the Chief Legal & Compliance Officer and a Director—sold a combined $613K in open-market transactions over a 5-day window, with the larger $475K sale occurring after the smaller $138K sale. These are routine insider sales relative to the company's $672M market cap (0.09%), and the legal officer's sale is consistent with standard liquidity/vesting activity rather than a bearish signal. The event is neutral with low market impact.

Key Financial Metrics

Direction
selling
Total Value
$613.0K
Insiders
2

Key Facts

  • Two insiders sold a combined $613K in shares over 5 days.
  • Chief Legal & Compliance Officer sold ~$475K at $11.13/sh; Director sold ~$138K at $11.25/sh.
  • Total sales represent ~0.09% of $672M market cap—trivial proportion.
  • No open-market insider purchases recorded in this cluster.

Financial Impact

Total insider sales of $613K represent ~0.09% of market cap, immaterial.

Risk Factors

  • Legal officer's large sale could reflect pre-planned 10b5-1 program or personal liquidity—indistinguishable from informational selling without additional context.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ZVRA-1787033800055
4 reports for ZVRA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ZVRA — sortable, filterable
TypeNow
Aug 17, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$11.57awaiting T+60—$9.83 (−15.04%)
May 6, 2026
24w ago
8-K
BULLISH ★ 6/10
$11.00 $10.06▼ −8.59%▼ −12.42%$9.83 (−10.64%)
Apr 22, 2026
26w ago
Press Release
NEUTRAL ★ 1/10
$10.49 $12.77▲ +21.73%▲ +16.96%$9.83 (−6.29%)
Mar 2, 2026
34w ago
Press Release
NEUTRAL ★ 3/10
$9.09 $10.32▲ +13.53%▲ +4.20%$9.83 (+8.14%)
Showing 4 of 4

US Market Status

Market Open — Closes in 6h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 18, 2026